February 13, 2026
Amgen receives EC approval for Uplizna in generalised myasthenia gravis
Amgen has secured approval from the European Commission (EC) for Uplizna (inebilizumab) as an add-on treatment to standard therapy for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







